Eli Lilly
One of the world's largest pharmaceutical companies, pioneering treatments in diabetes, obesity, oncology, and neuroscience.
Eli Lilly Q4 2024 Financial Results – Investor RelationsEli Lilly and Company is a global pharmaceutical giant founded in May 1876 in Indianapolis, Indiana, by pharmaceutical chemist Colonel Eli Lilly. Headquartered at Lilly Corporate Center in Indianapolis and led by Chair and CEO David A. Ricks, the company employs more than 50,000 people worldwide and trades on the NYSE under the ticker LLY.
Lilly's portfolio spans therapeutic areas including diabetes/obesity, oncology, immunology, neuroscience, and cardiovascular disease. Well-known products include Prozac, Cialis, Zyprexa, and diabetes and obesity medications Trulicity, Mounjaro, Jardiance, and Zepbound. In July 2024, the FDA granted full approval to Kisunla (donanemab), Lilly's Alzheimer's treatment, marking a significant milestone in neurodegeneration.
The company reported full-year 2024 worldwide revenue of approximately $45.0 billion, a 32% increase year-over-year, with Q4 2024 revenue of $13.53 billion representing 45% growth versus Q4 2023. Since 2020, Lilly has committed more than $55 billion globally to expand manufacturing capacity, with over $50 billion invested in the United States alone.
Lilly is actively integrating AI and advanced computing into drug discovery, including a $1 billion collaboration with NVIDIA to build a supercomputer for molecular simulations and large-scale AI model training. A 2024 partnership with Amazon Pharmacy enables home delivery of medications such as Zepbound through the LillyDirect platform, reflecting the company's push into direct-to-patient innovation.
Ideas that could help Eli Lilly
- SLC25A45-Based GLP-1RA Responder Diagnostic
A companion diagnostic that uses SLC25A45 genetic variants and plasma trimethyllysine-to-carnitine ratios to predict whether a patient will lose adipose tissue on GLP-1 receptor agonist therapy (e.g., semaglutide, tirzepatide) before expensive treatment begins.
Why it helps: Eli Lilly's tirzepatide (Mounjaro/Zepbound) faces the same non-responder challenge; a validated SLC25A45 stratification tool would help optimize patient selection and support real-world evidence programs.
- Non-Hallucinogenic TrkB Positive Allosteric Modulator (PAM) Antidepressant
A drug that mimics the fast-acting antidepressant and neuroplasticity effects of psychedelics by directly binding the BDNF receptor TrkB at high affinity, without activating serotonin 5-HT2A receptors and thus without hallucinations.
Why it helps: Eli Lilly has deep antidepressant history (fluoxetine) and has recently re-entered CNS with lasmiditan; a high-affinity TrkB PAM represents a scientifically differentiated antidepressant asset they could acquire or develop.